Aurobindo Pharma shares gained 1.4 percent in the opening trade on June 5 after the company received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Tofacitinib tablets, 5 mg and 10 mg, the generic version of PF Prism C.V.'s Xeljanz Tablets.

At 09:20am, Aurobindo Pharma was quoting at Rs 1,484.05, up Rs 20.45, or 1.40 percent, on the BSE.

The approved product is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis (UC).

The drug will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of Aurobindo Pharma, and is set for an immediate launch in the US market.

The company on June 3 inaugurated TheraNym, one of India's largest dedicated biologics contract manufacturing organisations (CMOs).

In the previous trading session, the share closed at Rs 1,463.60, up Rs 23.30, or 1.62 percent.

The share touched a 52-week high of Rs 1,550.00 and a 52-week low of Rs 1,017.00 on 21 May, 2026 and 02 September, 2025, respectively. Currently, the stock is trading 5.57 percent below its 52-week high and 43.91 percent above its 52-week low.

The market capitalisation of the company stands at Rs 85,006.13 crore.